Retatrutide (development code LY3437943) is a synthetic 39-residue peptide studied as a triple agonist at the GIP, GLP-1, and glucagon receptors. It belongs to the incretin class of metabolic research compounds and is investigated in preclinical models of receptor signaling and metabolic pathways.

As a large, lipid-modified peptide it has no single clean small-molecule registry entry, which is common for compounds of this class. NOVA Q supplies it strictly as a reference material for in-vitro laboratory research use only, characterized and released per lot.

Tirzepatide (development code LY3298176) is a synthetic peptide studied as a dual agonist at the GIP and GLP-1 receptors, and a widely referenced compound in incretin-receptor pharmacology research.

Tirzepatide is an approved active pharmaceutical ingredient. NOVA Q supplies it exclusively as a characterized reference material for laboratory research use only, not for human or veterinary use. Each lot is released against its own certificate of analysis.

GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine (GHK), also known as copper tripeptide-1. The GHK sequence binds copper with high affinity, and the resulting complex is studied in preclinical and in-vitro research on skin and connective-tissue biology.

The structure shown is the GHK peptide; in the complex it coordinates a copper(II) ion. NOVA Q supplies GHK-Cu as a reference material characterized for identity and purity, for research use only.

Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH), a 44-residue peptide carrying a modified N-terminus that is studied for its stability relative to native GHRH. It is investigated in preclinical research on the GH/GHRH axis.

NOVA Q supplies tesamorelin as a lyophilized reference material for laboratory research use only, characterized and released against a lot-specific certificate of analysis.

NAD+ (β-nicotinamide adenine dinucleotide) is a coenzyme central to cellular redox reactions and energy metabolism, present in all living cells. Unlike the peptides in this catalog it is a defined small molecule with a single registry entry and a well-characterized structure.

As a reference standard it is widely used in biochemical and in-vitro research. NOVA Q supplies it as a characterized reference material for laboratory research use only.

KPV is a tripeptide, lysine-proline-valine, corresponding to the C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). It is studied in preclinical and in-vitro models of inflammatory signaling.

As a short, well-defined peptide it reconstitutes readily and is straightforward to characterize. NOVA Q supplies it as a lyophilized reference material for laboratory research use only.

TB-500 is a synthetic peptide corresponding to the acetylated actin-binding region (residues 17-23, Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln) of thymosin beta-4, an actin-sequestering protein. This fragment is the species identified in analytical characterization of TB-500 in the research literature.

It is studied in preclinical and in-vitro research on cell motility and tissue biology. The structure shown is the heptapeptide fragment; the parent protein thymosin beta-4 carries CAS 77591-33-4. NOVA Q supplies TB-500 as a reference material for research use only.

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide and a melanocortin-receptor agonist, structurally related to alpha-MSH. It is studied in preclinical research on melanocortin-receptor signaling.

NOVA Q supplies it as a reference material for laboratory research use only, not for human or veterinary use. Each lot is characterized and released against its own certificate of analysis.

Wolverine is a NOVA Q research blend combining BPC-157 and TB-500 in a 1:1 ratio within a single reconstitutable vial, supplied in 10 mg (5 + 5) and 20 mg (10 + 10) total sizes.

Each component is a characterized reference material in its own right; the blend is supplied for laboratory research use only. See the BPC-157 and TB-500 monographs for the identity data of each component.

KLOW is a four-component NOVA Q research blend in a single vial, 80 mg total: BPC-157 10 mg, GHK-Cu 50 mg, TB-500 10 mg, and KPV 10 mg.

It is supplied as a combined reference material for laboratory research use only. The identity and purity data for each component are given on that component’s own monograph.

This NOVA Q research blend combines CJC-1295 without DAC, a growth-hormone-releasing hormone (GHRH) analog, and ipamorelin, a growth-hormone secretagogue and ghrelin-receptor agonist, in a single vial. The two are studied together in preclinical research on the GH axis.

Supplied as a combined reference material for laboratory research use only. Each component is characterized before blending.